source
- Cerevance reports positive Phase 3 results for Parkinson’s drug solengeprasCerevance, a Boston biotech spinout from Takeda, announced that its experimental Parkinson’s drug solengepras achieved its primary endpoint in a Phase 3 trial. The trial enrolled 341 patients with…
- Matchpoint Therapeutics raises $150M Series B to advance oral covalent therapies for autoimmune diseaseMatchpoint Therapeutics announced a $150 million Series B financing round. The round was co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures, Digitalis Ventures, Invus, BB…